We provide you with 20 years of free, institutional-grade data for ORIC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ORIC. Explore the full financial landscape of ORIC stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about ORIC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
ORIC Pharmaceuticals, Inc(NASDAQ:ORIC) 
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of ...
Website: http://www.oricpharma.com
Full Time Employees: 60
CEO: Jacob M. Chacko
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends